1. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
- Author
-
Clovis A. Silva, Ana C. Medeiros-Ribeiro, Leonard V. K. Kupa, Emily F. N. Yuki, Sandra G. Pasoto, Carla G. S. Saad, Solange R. G. Fusco, Rosa M. R. Pereira, Samuel K. Shinjo, Ari S. R. Halpern, Eduardo F. Borba, Fernando H. C. Souza, Lissiane K. N. Guedes, Renata Miossi, Karina R. Bonfiglioli, Diogo S. Domiciano, Andrea Y. Shimabuco, Danieli C. O. Andrade, Luciana P. C. Seguro, Ricardo Fuller, Percival D. Sampaio-Barros, Ana P. L. Assad, Julio C. B. Moraes, Claudia Goldenstein-Schainberg, Henrique A. M. Giardini, Henrique C. Silva, Victor A. O. Martins, Lorena E. B. Villamarin, Renata S. Novellino, Lucas P. Sales, Carlo S. R. Araújo, Matheus S. R. Silva, Dilson M. N. Filho, Marta H. Lopes, Alberto J. S. Duarte, Esper G. Kallas, Nadia E. Aikawa, and Eloisa Bonfa
- Subjects
Science - Abstract
Characterising the response to SARS-CoV-2 post vaccination is critical in the appraisement of the induced immune response, performance and protective potential. Here the authors present data from a phase 4 clinical trial in autoimmune rheumatic disease patients 6 months post second dose of Sinovac-CoronaVac inactivated vaccine that show a marked reduction in antibody particularly in males or those under treatment with immune targeting therapies but saw no rise in COVID-19 disease.
- Published
- 2022
- Full Text
- View/download PDF